{"success":true,"data":{"pressRelease":{"id":"121880","rtpr_id":"nPnbDyy3Xa","ticker":"1548","exchange":"HKEX","all_tickers":["1548"],"title":"GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles","author":"PR Newswire","published_at":"2026-08-18T14:00:06.251Z","article_body":"GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles\n\nPR Newswire\n\nPISCATAWAY, N.J., Aug. 18, 2026\n\nAdjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of\nGenScript Life Science Group revenue\n\nPISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation\n(HKEX: 1548) reported first-half revenue of approximately US$404.2 million on\na comparable basis, up 27.3% year over year, while adjusted net profit rose\n203.3% to approximately US$62.5 million. The results reflect strong growth\nacross its core businesses, improved operating efficiency, and accelerating\ndemand for AI-enabled drug discovery services.\n\nThe AI-enabled drug discovery business doubled year over year and maintained\nrapid growth for a third consecutive half-year reporting period, driven by\ndemand from AI-focused biotechnology companies and pharmaceutical innovators.\nGene-to-Protein accounted for approximately 66% of GenScript Life Science\nGroup revenue and remained the company's primary growth engine.\n\nGenScript's Gene-to-Protein platform combines scientific expertise,\nautomation, and global manufacturing capacity in an integrated workflow\nspanning discovery, experimental validation, early development, and production\nsupport. As AI increases the scale and complexity of drug discovery, these\ncapabilities help customers validate candidates and advance programs with\ngreater speed and reliability.\n\n\"Our first-half results reflect strong execution across the portfolio, with\nour core businesses driving both revenue growth and improved profitability,\"\nsaid Sherry Shao, Rotating CEO of GenScript. \"We see significant long-term\nopportunity as AI reshapes life sciences and increases demand for experimental\nvalidation and development services. By expanding our global Gene-to-Protein\nplatform, automation, digital manufacturing, and delivery network, we are\nstrengthening GenScript's role as a critical infrastructure partner for\nAI-enabled drug discovery.\"\n\nFirst-Half 2026 Highlights\n\nGenScript Life Science Group\n\n * Revenue of approximately US$319.0 million, up 28.8%\n * Adjusted gross profit of approximately US$184.5 million, up 46.1%\n * Adjusted operating profit of approximately US$94.0 million, up 102.8%\n * Gene-to-Protein accounted for approximately 66% of segment revenue and\nremained the primary growth engine\nAI-Enabled Drug Discovery\n\n * AI-enabled drug discovery business doubled year over year and maintained rapid\ngrowth for a third consecutive half-year reporting period\n * Growth reflects deeper engagement with AI drug discovery companies and\nincreasing demand for protein engineering, biologics discovery, and\ndevelopment services, reinforcing GenScript's position as a validation and\ninfrastructure partner within the AI drug discovery ecosystem\nProBio\n\n * Revenue increased 34.2% on a comparable basis to approximately US$61.1\nmillion\n * New orders increased 54%\n * Adjusted operating loss narrowed 22.5% to US$24.3 million\n * Continued order growth and improving operating efficiency support ProBio's\nexpectation of achieving positive adjusted earnings before interest, taxes,\ndepreciation, and amortization (EBITDA) by 2027\nBestzyme\n\n * Revenue of approximately US$30.4 million, up 7.4%\n * Adjusted gross profit of approximately US$13.0 million, up 14.0%\nIntegrated Capabilities Support Growth Across the Portfolio\n\nThe recovery in global biopharmaceutical research activity and the expanding\nuse of AI are increasing the number and complexity of programs moving from\ncomputational design into experimental validation, development, and\nproduction. This shift is creating demand for integrated scientific,\nautomation, and manufacturing infrastructure that can support customers across\nthe drug-development workflow.\n\nGenScript connects gene synthesis, protein production, antibody discovery,\nbiologics development, automation, and global manufacturing in a single\nworkflow. This infrastructure enables AI-focused biotechnology companies and\npharmaceutical innovators to validate more candidates, identify viable\nprograms, and advance them through early development and production without\ncoordinating multiple service providers.\n\nTo support rising demand, GenScript continues to invest across its global\ndiscovery and manufacturing network, expanding capacity, shortening turnaround\ntimes, and enhancing automation and digital workflows. These investments are\nimproving consistency and scalability as AI-driven customer projects grow\nincreasingly complex.\n\nAcross the portfolio, ProBio benefited from growing demand for biologics\ndevelopment and manufacturing services while improving operating performance\nand building an order base that supports future revenue growth. Bestzyme\ncontinues to invest in enzyme engineering and AI-enabled synthetic biology\ntechnologies designed to improve research efficiency, reduce production costs,\nand accelerate new product development.\n\nOutlook\n\nGenScript enters the second half of 2026 with continued momentum across\nGenScript Life Science Group, ProBio, and Bestzyme, supported by a growing\norder base across its core businesses.\n\nThe company expects higher demand, increased utilization across its global\nnetwork, and further operating leverage to support continued revenue growth\nand profitability improvement. Ongoing investment in technology, automation,\nand capacity is expanding GenScript's ability to support larger and more\ncomplex AI-enabled drug discovery programs, while ProBio's growing order base\nand Bestzyme's enzyme engineering and AI-enabled synthetic biology\ncapabilities provide additional platforms for long-term growth. As adoption\nexpands across these businesses, GenScript expects to deepen customer\nrelationships, strengthen global delivery, and build its position as a\ncritical infrastructure partner supporting next-generation therapeutic and\nbiotechnology innovation.\n\nAdditional financial information, including consolidated and segment results,\nis available in GenScript's First-Half 2026 Results Announcement published on\nThe Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the\nGenScript website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4754645-1&h=624578825&u=https%3A%2F%2Fwww.genscript.com%2Fannual-results-packages.html&a=GenScript+website)\n.\n\nAbout GenScript Biotech Corporation\n\nFounded in New Jersey in 2002, GenScript Biotech Corporation supports\nbiotechnology and healthcare innovation through its integrated portfolio of\nresearch, development, and manufacturing services. Guided by its mission to\nMake People and Nature Healthier Through Biotechnology, GenScript has more\nthan 6,100 employees and serves over 200,000 customers across more than 100\ncountries and regions, including the world's top 20 pharmaceutical companies.\nFor more information, visit www.genscript.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4754645-1&h=1084775059&u=http%3A%2F%2Fwww.genscript.com%2F&a=www.genscript.com)\n.\n\nInvestor and Media Contacts\n\nInvestor Relations\nEmail: ir@genscript.com (mailto:ir@genscript.com)\n\nMedia Contact\nKate Grusich, Senior Corporate Communications Manager\nKatherina.Grusich@genscript.com (mailto:Katherina.Grusich@genscript.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles-302854161.html\n(https://www.prnewswire.com/news-releases/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles-302854161.html)\n\nSOURCE GenScript Biotech Corporation\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1971480/GBC_mid-year.jpg?id=OA2893461\nhttps://mmx.prnewswire.com/media/MS1775941/GenScript-Logo.jpg?id=OA2893464\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbDyy3Xa","title":"GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles","author":"PR Newswire","ticker":"1548","created":"2026-08-18T14:00:06.251Z","tickers":["1548"],"exchange":"HKEX","article_body":"GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles\n\nPR Newswire\n\nPISCATAWAY, N.J., Aug. 18, 2026\n\nAdjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of\nGenScript Life Science Group revenue\n\nPISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation\n(HKEX: 1548) reported first-half revenue of approximately US$404.2 million on\na comparable basis, up 27.3% year over year, while adjusted net profit rose\n203.3% to approximately US$62.5 million. The results reflect strong growth\nacross its core businesses, improved operating efficiency, and accelerating\ndemand for AI-enabled drug discovery services.\n\nThe AI-enabled drug discovery business doubled year over year and maintained\nrapid growth for a third consecutive half-year reporting period, driven by\ndemand from AI-focused biotechnology companies and pharmaceutical innovators.\nGene-to-Protein accounted for approximately 66% of GenScript Life Science\nGroup revenue and remained the company's primary growth engine.\n\nGenScript's Gene-to-Protein platform combines scientific expertise,\nautomation, and global manufacturing capacity in an integrated workflow\nspanning discovery, experimental validation, early development, and production\nsupport. As AI increases the scale and complexity of drug discovery, these\ncapabilities help customers validate candidates and advance programs with\ngreater speed and reliability.\n\n\"Our first-half results reflect strong execution across the portfolio, with\nour core businesses driving both revenue growth and improved profitability,\"\nsaid Sherry Shao, Rotating CEO of GenScript. \"We see significant long-term\nopportunity as AI reshapes life sciences and increases demand for experimental\nvalidation and development services. By expanding our global Gene-to-Protein\nplatform, automation, digital manufacturing, and delivery network, we are\nstrengthening GenScript's role as a critical infrastructure partner for\nAI-enabled drug discovery.\"\n\nFirst-Half 2026 Highlights\n\nGenScript Life Science Group\n\n * Revenue of approximately US$319.0 million, up 28.8%\n * Adjusted gross profit of approximately US$184.5 million, up 46.1%\n * Adjusted operating profit of approximately US$94.0 million, up 102.8%\n * Gene-to-Protein accounted for approximately 66% of segment revenue and\nremained the primary growth engine\nAI-Enabled Drug Discovery\n\n * AI-enabled drug discovery business doubled year over year and maintained rapid\ngrowth for a third consecutive half-year reporting period\n * Growth reflects deeper engagement with AI drug discovery companies and\nincreasing demand for protein engineering, biologics discovery, and\ndevelopment services, reinforcing GenScript's position as a validation and\ninfrastructure partner within the AI drug discovery ecosystem\nProBio\n\n * Revenue increased 34.2% on a comparable basis to approximately US$61.1\nmillion\n * New orders increased 54%\n * Adjusted operating loss narrowed 22.5% to US$24.3 million\n * Continued order growth and improving operating efficiency support ProBio's\nexpectation of achieving positive adjusted earnings before interest, taxes,\ndepreciation, and amortization (EBITDA) by 2027\nBestzyme\n\n * Revenue of approximately US$30.4 million, up 7.4%\n * Adjusted gross profit of approximately US$13.0 million, up 14.0%\nIntegrated Capabilities Support Growth Across the Portfolio\n\nThe recovery in global biopharmaceutical research activity and the expanding\nuse of AI are increasing the number and complexity of programs moving from\ncomputational design into experimental validation, development, and\nproduction. This shift is creating demand for integrated scientific,\nautomation, and manufacturing infrastructure that can support customers across\nthe drug-development workflow.\n\nGenScript connects gene synthesis, protein production, antibody discovery,\nbiologics development, automation, and global manufacturing in a single\nworkflow. This infrastructure enables AI-focused biotechnology companies and\npharmaceutical innovators to validate more candidates, identify viable\nprograms, and advance them through early development and production without\ncoordinating multiple service providers.\n\nTo support rising demand, GenScript continues to invest across its global\ndiscovery and manufacturing network, expanding capacity, shortening turnaround\ntimes, and enhancing automation and digital workflows. These investments are\nimproving consistency and scalability as AI-driven customer projects grow\nincreasingly complex.\n\nAcross the portfolio, ProBio benefited from growing demand for biologics\ndevelopment and manufacturing services while improving operating performance\nand building an order base that supports future revenue growth. Bestzyme\ncontinues to invest in enzyme engineering and AI-enabled synthetic biology\ntechnologies designed to improve research efficiency, reduce production costs,\nand accelerate new product development.\n\nOutlook\n\nGenScript enters the second half of 2026 with continued momentum across\nGenScript Life Science Group, ProBio, and Bestzyme, supported by a growing\norder base across its core businesses.\n\nThe company expects higher demand, increased utilization across its global\nnetwork, and further operating leverage to support continued revenue growth\nand profitability improvement. Ongoing investment in technology, automation,\nand capacity is expanding GenScript's ability to support larger and more\ncomplex AI-enabled drug discovery programs, while ProBio's growing order base\nand Bestzyme's enzyme engineering and AI-enabled synthetic biology\ncapabilities provide additional platforms for long-term growth. As adoption\nexpands across these businesses, GenScript expects to deepen customer\nrelationships, strengthen global delivery, and build its position as a\ncritical infrastructure partner supporting next-generation therapeutic and\nbiotechnology innovation.\n\nAdditional financial information, including consolidated and segment results,\nis available in GenScript's First-Half 2026 Results Announcement published on\nThe Stock Exchange of Hong Kong Limited on August 16, 2026, as well as on the\nGenScript website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4754645-1&h=624578825&u=https%3A%2F%2Fwww.genscript.com%2Fannual-results-packages.html&a=GenScript+website)\n.\n\nAbout GenScript Biotech Corporation\n\nFounded in New Jersey in 2002, GenScript Biotech Corporation supports\nbiotechnology and healthcare innovation through its integrated portfolio of\nresearch, development, and manufacturing services. Guided by its mission to\nMake People and Nature Healthier Through Biotechnology, GenScript has more\nthan 6,100 employees and serves over 200,000 customers across more than 100\ncountries and regions, including the world's top 20 pharmaceutical companies.\nFor more information, visit www.genscript.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4754645-1&h=1084775059&u=http%3A%2F%2Fwww.genscript.com%2F&a=www.genscript.com)\n.\n\nInvestor and Media Contacts\n\nInvestor Relations\nEmail: ir@genscript.com (mailto:ir@genscript.com)\n\nMedia Contact\nKate Grusich, Senior Corporate Communications Manager\nKatherina.Grusich@genscript.com (mailto:Katherina.Grusich@genscript.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles-302854161.html\n(https://www.prnewswire.com/news-releases/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles-302854161.html)\n\nSOURCE GenScript Biotech Corporation\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1971480/GBC_mid-year.jpg?id=OA2893461\nhttps://mmx.prnewswire.com/media/MS1775941/GenScript-Logo.jpg?id=OA2893464\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-18T14:00:08.054151064Z","server_sent_at_ms":1787061608054},"received_at":"2026-08-18T14:00:08.107Z","source_url":"https://www.prnewswire.com/news-releases/genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles-302854161.html"},"analysis":{"id":"110863","press_release_id":"121880","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"GenScript reported first-half revenue of $404.2 million, up 27.3% year-over-year, while adjusted net profit surged 203.3% to $62.5 million driven by strong execution across its portfolio.\n\nThe AI-enabled drug discovery business doubled year-over-year, and the Gene-to-Protein platform accounted for 66% of Life Science Group revenue, which grew 28.8% to $319.0 million.\n\nProBio revenue increased 34.2% to $61.1 million with narrowing operating losses, and Bestzyme revenue grew 7.4% to $30.4 million, supported by ongoing investments in enzyme engineering.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"GenScript H1: Revenue jumps 27% and profit triples as AI drug discovery business doubles."},"keyFigures":{"revenue":404200000,"revenueYoy":"27.3%","customDimensions":{"probio_revenue":61100000,"bestzyme_revenue":30400000,"adjusted_net_profit":62500000,"probio_revenue_growth":"34.2%","bestzyme_revenue_growth":"7.4%","adjusted_operating_profit":94000000,"adjusted_net_profit_growth":"203.3%","life_science_group_revenue":319000000,"adjusted_operating_profit_growth":"102.8%","life_science_group_revenue_growth":"28.8%"}},"quotedText":"Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability","namedEntities":{"people":[{"name":"Sherry Shao","role":"Rotating CEO"},{"name":"Kate Grusich","role":"Senior Corporate Communications Manager"}],"products":["Gene-to-Protein","AI-enabled drug discovery"],"companies":[{"name":"GenScript Biotech Corporation","ticker":"1548"}],"dollarAmounts":[{"amount":"US$404.2 million","context":"first-half revenue"},{"amount":"US$62.5 million","context":"adjusted net profit"},{"amount":"US$319.0 million","context":"GenScript Life Science Group revenue"},{"amount":"US$184.5 million","context":"Adjusted gross profit"},{"amount":"US$94.0 million","context":"Adjusted operating profit"},{"amount":"US$61.1 million","context":"ProBio revenue"},{"amount":"US$24.3 million","context":"ProBio adjusted operating loss"},{"amount":"US$30.4 million","context":"Bestzyme revenue"},{"amount":"US$13.0 million","context":"Bestzyme adjusted gross profit"}]},"materialImpact":{"score":4,"reasoning":"Reported strong first-half results with revenue growing 27.3% year-over-year to $404.2 million and adjusted net profit surging 203.3% to $62.5 million. The doubling of the AI drug discovery business and significant margin expansion indicate accelerating operational leverage."},"tickerRelevance":{"others":[],"primary":"1548"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"strong_earnings","sectorWeight":"health_care","narrativeBoost":"AI_drug_discovery"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"GenScript reported first-half revenue of $404.2 million, up 27.3% year-over-year, while adjusted net profit surged 203.3% to $62.5 million driven by strong execution across its portfolio.\n\nThe AI-enabled drug discovery business doubled year-over-year, and the Gene-to-Protein platform accounted for 66% of Life Science Group revenue, which grew 28.8% to $319.0 million.\n\nProBio revenue increased 34.2% to $61.1 million with narrowing operating losses, and Bestzyme revenue grew 7.4% to $30.4 million, supported by ongoing investments in enzyme engineering.","key_figures":{"revenue":404200000,"revenueYoy":"27.3%","customDimensions":{"probio_revenue":61100000,"bestzyme_revenue":30400000,"adjusted_net_profit":62500000,"probio_revenue_growth":"34.2%","bestzyme_revenue_growth":"7.4%","adjusted_operating_profit":94000000,"adjusted_net_profit_growth":"203.3%","life_science_group_revenue":319000000,"adjusted_operating_profit_growth":"102.8%","life_science_group_revenue_growth":"28.8%"}},"named_entities":{"people":[{"name":"Sherry Shao","role":"Rotating CEO"},{"name":"Kate Grusich","role":"Senior Corporate Communications Manager"}],"products":["Gene-to-Protein","AI-enabled drug discovery"],"companies":[{"name":"GenScript Biotech Corporation","ticker":"1548"}],"dollarAmounts":[{"amount":"US$404.2 million","context":"first-half revenue"},{"amount":"US$62.5 million","context":"adjusted net profit"},{"amount":"US$319.0 million","context":"GenScript Life Science Group revenue"},{"amount":"US$184.5 million","context":"Adjusted gross profit"},{"amount":"US$94.0 million","context":"Adjusted operating profit"},{"amount":"US$61.1 million","context":"ProBio revenue"},{"amount":"US$24.3 million","context":"ProBio adjusted operating loss"},{"amount":"US$30.4 million","context":"Bestzyme revenue"},{"amount":"US$13.0 million","context":"Bestzyme adjusted gross profit"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-18T16:21:21.668Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap","eventGravity":"strong_earnings","sectorWeight":"health_care","narrativeBoost":"AI_drug_discovery"}},"durationMs":94577,"modelName":"glm-4.7"}}